Background: Patients with end stage renal disease (ESRD) are at significantly increased risk for both thrombosis and bleeding relative to those with normal renal function, which makes anticoagulation particularly challenging. Evidence suggests that rivaroxaban and dabigatran are associated with a higher risk of bleeding in ESRD patients. To date, no large national cohort studies have [...]

Background: Arterial (3-fold) and venous (10-fold) thromboembolism are more common in myeloproliferative neoplasm (MPN) than general population with rates as high as 50% in polycythemia vera (PV) and essential thrombocythemia (ET).1,2 While primary prophylaxis with aspirin is not debated for prevention of arterial and venous thromboembolism, the choice of anticoagulant for secondary prophylaxis and treatment [...]

Background: Direct acting oral anticoagulants (DOACs) have been approved for conditions such as non-valvular atrial fibrillation and venous thromboembolism. High quality randomized controlled trials have demonstrated the safety and efficacy of DOACs as compared to warfarin with exceptions in specific patient populations (such as those with mechanical heart valves). DOACs are more convenient and generally [...]